After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

Among men with PSA persistence after radical prostatectomy, a higher preoperative PSA surprisingly was linked to lower mortality. Men with PSA persistence and preoperative PSA >20 ng/mL had 31% lower ...

Higher persistent PSA levels post-surgery were linked to increased mortality risk, with 8-year prostate cancer–specific mortality reaching 13.86% for a prostate-specific antigen (PSA) ≥ 1 ng/mL. The ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression. Among patients with intermediate-risk prostate cancer, ...

The journey through prostate cancer treatment marks a significant chapter in many men’s lives, with surgery often serving as a pivotal turning point toward recovery. While the removal of cancerous ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT), a form of high-dose radiation delivered in just five sessions, after ...

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

NASHVILLE -- Testosterone replacement remains controversial in men who have been treated for prostate cancer, but new data from New York's Memorial Sloan Kettering Cancer Center (MSKCC) reported here ...